A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain
Citations Over TimeTop 10% of 2013 papers
Abstract
Neuropathic pain (NeP) is generally considered an intractable problem, which becomes compelling in clinical practice when caused by highly effective chemotherapeutics, such as in the treatment of cancer with oxaliplatin (OXA) and related drugs. In the present work we describe a structurally new compound, ADM_09, which proved to effectively revert OXA-induced NeP in vivo in rats without eliciting the commonly observed negative side-effects. ADM_09 does not modify normal behavior in rats, does not show any toxicity toward astrocyte cell cultures, nor any significant cardiotoxicity. Patch-clamp recordings demonstrated that ADM_09 is an effective antagonist of the nociceptive sensor channel TRPA1, which persistently blocks mouse as well as human variants of TRPA1. A dual-binding mode of action has been proposed for ADM_09, in which a synergic combination of calcium-mediated binding of the carnosine residue and disulphide-bridge-forming of the lipoic acid residue accounts for the observed persistent blocking activity toward the TRPA1 channel.
Related Papers
- The cardiotoxicity of anticancer agents.(1982)
- → Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis(2021)5 cited
- mFOLFOX6/Bevacizumabによる治療開始後に脾臓が増大しOxaliplatin休薬により脾臓が縮小した大腸癌の2 例(2011)
- Oxaliplatin─Based Chemotherapy の腹膜播種を伴うStage IV 大腸癌に対する効果(2013)
- → 03:00 PM Abstract No. 316 Morphology, loadability, and releasing profiles of CalliSpheres microspheres in delivering oxaliplatin: an in vitro study(2019)